OPKO Health Inc (NAS:OPK)
$ 1.7 0.11 (6.92%) Market Cap: 1.07 Bil Enterprise Value: 1.18 Bil PE Ratio: 0 PB Ratio: 0.77 GF Score: 45/100

OPKO Health Inc at Piper Jaffray Healthcare Conference Transcript

Dec 04, 2019 / 05:30PM GMT
Release Date Price: $1.64 (+2.50%)
Edward Andrew Tenthoff
Piper Jaffray Companies, Research Division - MD & Senior Research Analyst

Good afternoon. My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Jaffray. And before I begin, I am required to point out certain disclosures regarding the relationship between Piper and our next presenting company, OPKO.

OPKO is a diversified health care company founded by Dr. Phil Frost. With partner Pfizer, the company recently reported positive Phase III data on somatrogon in pediatric growth hormone deficiency. The company also sells RAYALDEE for secondary hyperparathyroidism in stage 3, 4 chronic kidney disease patients who happen to have vitamin D deficiency. Beyond these, OPKO has an emerging pipeline -- therapeutic pipeline and also the BioReference and Genedx diagnostic labs businesses.

I'm pleased to introduce Executive Vice President Steve Rubin; CFO, Adam Logal, and also, Jon Cohen, who heads up BioReference and GeneDx. So thanks, guys, for being with us today.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot